WO2017004151A1 - Anti-apobec3 antibodies and methods of making and using - Google Patents

Abstract

Hybridoma cell lines produce monoclonal antibodies that specifically bind to an APOBEC3 protein. The antibodies can be used in various methods. In some aspects, an anti-APOBEC3 antibody may be immobilized to a substrate. In another aspect, this disclosure provides a vector that includes a nucleic acid sequence encoding antibody produced by a hybridoma cell line that produces an antibody that specifically binds to an APOBEC3 protein.

Description

ANTI- APOBEC 3 ANTIBODIES AND METHODS OF MAKING AND USING

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Patent Application No. 62/186,109, filed June 29, 2015, which is incorporated herein by reference.

SEQUENCE LISTING

This application contains a Sequence Listing electronically submitted via EFS-Web to the

United States Patent and Trademark Office as an ASCII text file entitled "2016-06-23-

SequenceListing_ST25.txt" having a size of 72 kilobytes and created on June 23, 2016. The information contained in the Sequence Listing is incorporated by reference herein.

BACKGROUND

APOBEC3B is an antiviral enzyme that has been implicated in cancer mutagenesis.

APOBEC3B is one of seven human cytidine deaminases in the APOBEC3 (A3) family. The A3 family includes APOBEC3A (A3 A); APOBEC3B (A3B); APOBEC3C (A3C); APOBEC3D (A3D) APOBEC3F (A3F); APOBEC3G (A3G); APOBEC3H (A3H).

SUMMARY

This disclosure describes antibodies that specifically bind to an APOBEC3 protein. In some embodiments, the antibody can specifically bind APOBEC3B.

In some embodiments, the antibody can be a monoclonal antibody. In some of these embodiments, the monoclonal antibody is produced by hybridoma cell line 5206-235-07. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5210-76-29. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5210-08-15. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5211-110-19. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5211-142-12. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5210-55-19. In other embodiments, the monoclonal antibody is produced by hybridoma cell line 5210-87-13. In some embodiments, the antibody can include at least one of the amino acid sequences SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14.

In some embodiments, the antibody can include at least one of the amino acid sequences SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, or SEQ ID NO:28.

In some embodiments, the monoclonal antibody can include a heavy chain and a light chain, wherein the light chain includes three complementarity determining regions (CDRs), and further wherein the first light chain CDR (CDR1) comprises at least one of the amino acid sequences QSVYNNND (SEQ ID NO:29), QSLYRNKN (SEQ ID NO:32), QNIYSN (SEQ ID NO:35),

QSVYNNKN (SEQ ID NO:38), HSVYNNNW (SEQ ID NO:40), QSVYKNKN (SEQ ID NO:42), or ESVFKKNW (SEQ ID NO:44).

In some embodiments, the monoclonal antibody includes a heavy chain and a light chain, wherein the light chain includes three complementarity determining regions (CDRs), and further wherein the second light chain CDR (CDR2) includes at least one of the amino acid sequences RAS

(SEQ ID NO:30), YAS (SEQ ID NO:33), or GAS (SEQ ID NO:36).

In some embodiments, the monoclonal antibody includes a heavy chain and a light chain, wherein the light chain includes three complementarity determining regions (CDRs), and further wherein the third light chain CDR (CDR3) includes at least one of the amino acid sequences LGSYDDDVDTCA (SEQ ID NO:31), QGEFSCSSADCFA (SEQ ID NO:34), QSYVYSSSTADT

(SEQ ID NO:37), LGEFYCSSIDCLV (SEQ ID NO:39), QGGYSSGDGIA (SEQ ID NO:41),

LGEFSCHSVDCLA (SEQ ID NO:43), or AGAFDGNIYP (SEQ ID NO:45).

In some embodiments, the monoclonal antibody includes a heavy chain and a light chain, wherein the heavy chain includes three complementarity determining regions (CDRs), and further wherein the first heavy chain CDR (CDR1) includes at least one of the amino acid sequences

GFDFSS (SEQ ID NO:46), GFSFSRG (SEQ ID NO:49), GFSFSDG (SEQ ID NO:52), GFSLSS

(SEQ ID NO:55), or GFSISS (SEQ ID NO:61).

In some embodiments, the monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain includes three complementarity determining regions (CDRs), and further wherein the second heavy chain CDR (CDR2) includes at least one of the amino acid sequences including YIDPVFG (SEQ ID NO:47), DMNIIAD (SEQ ID NO:50), CIYDASG (SEQ ID NO:53),

FINSDN (SEQ ID NO:56), IISSSG (SEQ ID NO:59), or SISSGG (SEQ ID NO:62). In some embodiments, the monoclonal antibody includes a heavy chain and a light chain, wherein the heavy chain includes three complementarity determining regions (CDRs), and further wherein the third heavy chain CDR (CDR3) includes at least one of the amino acid sequences FCARST (SEQ ID NO:48), FCVSGS (SEQ ID NO: 51), FCVKTD (SEQ ID NO: 54), FCATYR (SEQ ID NO:57), FCAREG (SEQ ID NO:60), or FCGS (SEQ ID NO:63).

In another aspect, this disclosure describes methods that involve using any of the antibodies summarized above. Some of these methods involve using the antibody as research reagent. Other methods involve using the antibody for at least one of a diagnostic test and a prognostic test.

In some embodiments, the method can include detecting expression of one or more APOBEC3 (A3) proteins. In some of these embodiments, the method can include detecting expression of APOBEC3B (A3B).

In some embodiments, the method can include performing at least one of enzyme-linked immunosorbent assays (ELISA), immunoblotting (IB), immunoprecipitation (IP),

immunohistochemistry (IHC), immunofiuorescent microscopy (IF), and flow cytometry (FLOW).

In another aspect, this disclosure describes a method of producing an antibody. Generally, the method includes immunizing a host animal with at least one of

WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO: 64) and

CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65), and harvesting a cell that produces an antibody that specifically binds to one or more members of the APOBEC3 family. In some embodiments, the method can involve immunizing the host animal with both

WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO: 64) and

CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65).

In another aspect, this disclosure describes a device that includes any embodiment of antibody summarized above immobilized to a substrate.

In another aspect, this disclosure describes hybridoma cell lines that produce an antibody that specifically binds to an APOBEC3 protein.

In another aspect, this disclosure describes a vector that includes a nucleic acid sequence encoding antibody produced by a hybridoma cell line that produces an antibody that specifically binds to an APOBEC3 protein.

As used herein, an "antibody" and "antibodies" (immunoglobulins) refer to at least one of a monoclonal antibody (including a full-length monoclonal antibody), a polyclonal antibody preparation, a rnulti specific antibody (e.g., bispecific antibodies) formed from at least two intact antibodies, a human antibody, a humanized antibody, a cameiized antibody, a chimeric antibody, a single-chain Fv (scFv), a single-chain antibody, a single domain antibody, a domain antibody, an antibody fragment including, without limitation, an Fab fragment, an F(ab')₂ fragment, an antibody fragment that exhibits the desired biological activity, a disulfide-iinked Fv (sdFv), an intrabody, or an epitope-binding fragment of any of the above. In particular, antibody includes an

immunoglobulin molecule and an immunologically active fragment of an immunoglobulin molecule, i.e., a molecule that contains an antigen-binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2) or subclass,

A "monoclonal antibodv," as used herein, refers to an antibodv, as defined above, obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies included in the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by immortal hybridoma cells that are un con laminated by other immunoglobulin producing cells. Alternatively, the monoclonal antibody may be produced by ceils stably or transiently transfected with the heavy and light chain genes encoding the monoclonal antibody. The modifier "monoclonal" indicates the character of the antibody, as defined above, as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring engineering of the antibody by any particular method. The term "monoclonal" is used herein to refer to an antibody, as defined above, that is derived from a clonal population of cells, including any eukaryotic, prokaryotic, or phage clone, and not the method by which the antibody was engineered.

An "antigen" and variations thereof refer to any material capable of raising an immune response in a subject challenged with the material. In various embodiments, an antigen may raise a cell-mediated immune response, a humoral immune response, or both. Suitable antigens may be synthetic or occur naturally and, when they occur naturally, may be endogenous (e.g., a self- antigen) or exogenous. Suitable antigenic materials include but are not limited to peptides or polypeptides (including a nucleic acid, at least a portion of which encodes the peptide or polypeptide); lipids; glycolipids; polysaccharides; carbohydrates; polynucleotides; prions; live or inactivated bacteria, viruses, fungi, or parasites; and bacterial, viral, fungal, protozoal, tumor- derived, or organism-derived immunogens, toxins or toxoids. An antigen may include one or more epitopes.

"Epitope" refers to a chemical moiety that exhibits specific binding to an antibody.

"Isolated" and variations thereof refer to a polypeptide that has been removed from its natural environment to any degree. For instance, an isolated polypeptide is a polypeptide that has been removed from a cell, and many of the other polypeptides, nucleic acids, and other cellular material of its natural environment are no longer present. The term "isolated" does not convey any specific degree to which the other cellular components are removed.

"Protein" refers to any sequence of two or more amino acid residues without regard to the length of the sequence, as well as any complex of two or more separately translated amino acid sequences. Protein also refers to amino acid sequences chemically modified to include a carbohydrate, a lipid, a nucleotide sequence, or any combination of carbohydrates, lipids, and/or nucleotide sequences. As used herein, "protein," "peptide," and "polypeptide" are used

interchangeably .

"Purified" and variations thereof refer to preparations in which the presence of a particular component is enriched, to any degree, relative to the unpurified starting material. Purification may be stated in any suitable terms such as, for example, increasing the concentration of the particular component in the preparation, increasing the molecular or weight/weight ratio of the particular component compared to a second component, etc.

"Specific" and variations thereof refer to having a differential or a non-general affinity, to any degree, for a particular target. As used herein, antibody that can "specifically bind" a polypeptide is antibody that interacts with an epitope of an antigen that induced the synthesis of the antibody, or interacts with a structurally related epitope. Accordingly, in describing an antibody, the terms "specific" and "specifically binds" do not imply or require that the antibody binds to one and only one target molecule.

The words "preferred" and "preferably" refer to embodiments of the invention that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention. The terms "comprises" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

Unless otherwise specified, "a," "an," "the," and "at least one" are used interchangeably and mean one or more than one.

Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

For any method disclosed herein that includes discrete steps, the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.

The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various

combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows an ELISA screen of mAb-containing supernatants from hybridoma clones. Cell media supernatant from hybridoma clones (5206-235, 5210-08, 5210-55, 5210-76, 5210-87, 5211-110, and 5210-142) was assayed for binding to A3Bctd-myc-(HIS)₆ purified protein (A3B-

CTD) in a standard ELISA assay. Binding was detected with an anti-rabbit HRP secondary antibody (1 :5000), visualized with tetramethylbenzidine (TMB) and quantified by spectroscopy at 450nm. The negative control in this assay was cell-free media supernatant from a hybridoma clone that did not express anti-A3B, and the positive control was a rabbit anti-A3G antibody (NIH AIDS Reagent Program 10201).

FIG. 2 shows an ELISA screen of mAb-containing supernatants from individual hybridoma clones. Cell-free supernatants from hybridoma single-clones (5206-235-07, 5210-08-15, 5210-55- 19, 5210-76-29, 5210-87-13, 5211-110-19, and 5211-142-12) were assayed for binding to A3B- CTD in a standard ELISA assay. Binding was detected with an anti-rabbit HRP secondary antibody (1 :5000), visualized with tetramethylbenzidine (TMB) and quantified by spectroscopy at 450nm. The negative control in this assay was cell-free media supernatant from a hybridoma clone that did not express anti-A3B, and the positive control was a rabbit anti-A3G antibody (NIH AIDS Reagent Program 10201).

FIG. 3 shows an immunoblot of each anti-A3B monoclonal antibody against the 7- membered APOBEC3 family. Cell lysates from 293T cells transiently transfected with each HA- tagged APOBEC3 protein (A3A-HA, A3B-HA, A3C-HA, A3D-HA, A3F-HA, A3G-HA, A3H-HA) or the expression vector alone were resolved by 12% SDS-PAGE and transferred to PVDF membrane. Membranes were probed with supernatant from each hybridoma cell line (5206-235-07, 5210-08-15, 5210-55-19, 5210-76-29, 5210-87-13, 5211-110-19, and 5211-142-12) at 1/3 dilution, anti-A3G (60100, ProteinTech, Chicago, IL) 1/1000, anti-HA (C29F4, Rabbit mAb 3724, Cell Signaling Technology, Danvers, MA) 1/1000, or anti -tubulin (MMS-407R, Covance, Emeryville, CA) 1/20,000. Membranes were further probed with the appropriate secondary antibodies including anti-rabbit IgG IR800CW (Odyssey 926-32211, LI-COR Biosciences, Lincoln, NE) 1/20,000 or anti-mouse IgG IR800CW (Odyssey 827-08364, LI-COR Biosciences, Lincoln, NE) 1/20,000 in 50% Blok (WBAVDP001, Millipore, Darmstadt, Germany) in PBS-T, (PBS, 0.1% Tween-20) and images were generated using LI-COR imaging (LI-COR Biosciences, Lincoln, NE).

FIG. 4 shows the immunofluorescence of over-expressed A3B-GFP in HeLa cells detected by anti-A3B hybridoma supernatants. HeLa cells were plated at 250,000/well in a 6 well plate. Cells were transfected with 200 ng of A3B-GFP construct (Lackey et al. J. Mol Bio. 2012; 419(5):301- 14). 16 hours later, cells were plated at 30,000 cells/chamber in an eight-chambered slide. 24 hours post plating, cells were fixed in 4% paraformaldehyde (PFA) for 1 hour, washed, and incubated in supernatant from hybridoma cell line 5210-08-15, hybridoma cell line 5210-55-19, hybridoma cell line 5210-76-29, hybridoma cell line 5210-87-13, or hybridoma cell line 5211-110-19 overnight at room temperature. Cells were washed five times with lx PBS and incubated in anti-rabbit- TRITC (1 :500) (111095144, Jackson ImmunoResearch Laboratories Inc., West Grove, PA) for one hour at 37°C, then allowed to return to room temperature for two hours. Following five lx PBS washes, nuclei were strained with Hoescht for 15 minutes at room temperature. Following two washes with lx PBS, slides were stored submerged in lx PBS at 4°C. Images taken at 60x magnification, with a 1 second TRITC exposure time (to normalize), cropped to 900 ^χ 900 pixels and scaled down to 10% size.

FIG. 5 shows intracellular staining of endogenous A3B in two cancer cell lines by flow cytometry (FLOW). OVCAR5 (Monks et al., 1991, J. Natl. Cancer Inst. 83 :757-766) and MDA-MB-

468 (ATCC HTB-132, ATCC, Manassas, VA) cells were transduced with lentiviruses encoding either a control or A3B-specific shRNA. Following drug selection (puromycin), cells were fixed in 1% paraformaldehyde and permeabilized in cold methanol. Cells were then incubated with rabbit anti-A3B 5210-87-13 for one hour at room temperature, followed by an anti -rabbit PE-conjugated secondary antibody for 20 minutes at room temperature in the dark. After a single PBS wash to remove unbound antibody, cells were analyzed on a flow cytometer. Cells with endogenous A3B depleted by shRNA have significantly lower average fluorescence intensity.

FIG. 6 shows intracellular staining of exogenous (transfected) A3 G in a cancer cell line by flow cytometry (FLOW). The SupTl 1 cell line was stably transfected with pcDNA3.1 (SupTl 1 + Vector) or pcDNA3.1 A3G-HA (SupTl 1 + A3G-HA). Cells were fixed in 1% paraformaldehyde and permeabilized in cold methanol. Cells were then incubated with rabbit anti-A3B 5210-87-13 or rabbit anti-5211-10-19 for one hour at room temperature, followed by an anti -Rabbit FITC- conjugated secondary antibody for 20 minutes at room temperature in the dark. Cells were analyzed on a cytometer.

FIG. 7 shows detection of endogenous A3B in various cancer cell lines treated with A3B shRNA or control shRNA (Burns et al., 2013, Nature 494(7437):366-370). (A) Lysates from various cancer cell lines (cervical (DOTC2 4510, ATCC CRL-7920, ATCC, Manassas, VA), bladder (T24, ATCC HTB-4, ATCC, Manassas, VA), breast (ZR-75-1, ATCC CRL-1500, ATCC, Manassas, VA), head and neck squamous cell carcinoma (JSQ3, Weichselbaum et al., 1988, Int. J. Radial Oncol. Biol. Phys. 15:575-579), and ovarian (OVCAR5, Monks et al., 1991, J. Natl. Cancer Inst. 83 :757-766)) were resolved by SDS-PAGE, transferred to PVDF membrane, immunoblotted with anti-human A3B mAb (5210-87-13) (1 :50) in 5% milk, 0.1% Tween 20 in PBS, and detected with anti-rabbit HRP secondary antibody. (B) Osteosarcoma (U-2 OS, ATCC HTB-96, ATCC, Manassas, VA) cells were transduced with shControl or shA3B constructs (Burns et al., 2013, Nature 494(7437): 366-370) and plated at 20,000 cells/chamber in eight-chamber slides. 24 hours after plating, cells were fixed in 4% PFA for 30 minutes. Slides were incubated in primary antibody (5210-87-13, diluted 1 :5) overnight at room temperature. Following five washes with lx PBS, cells were incubated at 37°C for one hour in anti-rabbit (anti-Rb) TRITC (1 :500) then cooled to room temperature for two hours. Following five washes withlx PBS, nuclei were stained with Hoescht dye for 15 minutes. Dye was removed and cells were stored at 4°C submerged in lx PBS. Images were taken at 60x magnification, cropped to 900 ^χ 900 pixels and scaled down to 10% size.

FIG. 8 shows the alignment of anti-human A3B hybridoma Ig light chain sequences. (A) A ClustalW alignment of anti-human A3B hybridoma Ig light chain nucleotide sequences including the Ig light chain nucleotide sequence from hybridoma cell line 5206-235-7 (SEQ ID NO: l), the Ig light chain nucleotide sequence from hybridoma cell line 5210-76-29 (SEQ ID NO:2), the Ig light chain nucleotide sequence from hybridoma cell line 5210-8-15 (SEQ ID NO:3), the Ig light chain nucleotide sequence from hybridoma cell line 5211-110-19 (SEQ ID NO:4); the Ig light chain nucleotide sequence from hybridoma cell line 5211-142-12 (SEQ ID NO: 5), the Ig light chain nucleotide sequence from hybridoma cell line 5210-55-19 (SEQ ID NO:6), and the Ig light chain nucleotide sequence from hybridoma cell line 5210-87-13 (SEQ ID NO:7). The peptide number indicates the peptide that was used in the original immunization; A3 binding specificity is listed on the right. (B) A ClustalW alignment of anti-human A3B hybridoma Ig light chain protein sequences including the Ig light chain protein sequence from hybridoma cell line 5206-235-7 (SEQ ID NO:8), the Ig light chain protein sequence from hybridoma cell line 5210-76-29 (SEQ ID NO: 9), the Ig light chain protein sequence from hybridoma cell line 5210-8-15 (SEQ ID NO: 10), the Ig light chain protein sequence from hybridoma cell line 5211-110-19 (SEQ ID NO: 11), the Ig light chain protein sequence from hybridoma cell line 5211-142-12 (SEQ ID NO: 12), the Ig light chain protein sequence from hybridoma cell line 5210-55-19 (SEQ ID NO: 13), the Ig light chain protein sequence from hybridoma cell line 5210-87-13 (SEQ ID NO: 14). The alignment shows framework (FR) domains and complementarity determining regions (CDR). Identical amino acids (*) and similar amino acids (:) are indicated below the sequence. The peptide number indicates the peptide that was used in the original immunization A3 binding specificity is listed on the right.

FIG. 9 shows the alignment of anti-human A3B hybridoma Ig heavy chain sequences. (A) A

ClustalW alignment of anti-human A3B hybridoma Ig heavy chain nucleotide sequences including the Ig heavy chain nucleotide sequence from hybridoma cell line 5206-235-7 (SEQ ID NO: 15), the Ig light heavy nucleotide sequence from hybridoma cell line 5210-76-29 (SEQ ID NO: 16), the Ig heavy chain nucleotide sequence from hybridoma cell line 5210-8-15 (SEQ ID NO: 17), the Ig heavy chain nucleotide sequence from hybridoma cell line 5211-110-19 (SEQ ID NO: 18); the Ig heavy chain nucleotide sequence from hybridoma cell line 5211-142-12 (SEQ ID NO: 19), the Ig heavy chain nucleotide sequence from hybridoma cell line 5210-55-19 (SEQ ID NO:20), and the Ig heavy chain nucleotide sequence from hybridoma cell line 5210-87-13 (SEQ ID NO:21). The peptide number indicates the peptide that was used in the original immunization; A3 binding specificity is listed on the right. (B) A ClustalW alignment of anti-human A3B Ig heavy chain protein sequences including the Ig heavy chain protein sequence from hybridoma cell line 5206- 235-7 (SEQ ID NO:22), the Ig heavy chain protein sequence from hybridoma cell line 5210-76-29 (SEQ ID NO:23), the Ig heavy chain protein sequence from hybridoma cell line 5210-8-15 (SEQ ID NO:24), the Ig heavy chain protein sequence from hybridoma cell line 5211-110-19 (SEQ ID NO:25), the Ig heavy chain protein sequence from hybridoma cell line 5211-142-12 (SEQ ID NO:26), the Ig heavy chain protein sequence from hybridoma cell line 5210-55-19 (SEQ ID

NO:27), the Ig heavy chain nucleotide sequence from hybridoma cell line 5210-87-13 (SEQ ID NO:28). The alignment shows framework (FR) domains, complementarity determining regions (CDR), diversity (D) and joining (JH) domains. Identical amino acids (*) and similar amino acids (:) are indicated below the sequence; A3 binding specificity is listed on the right. DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

This disclosure describes antibodies that bind to cytidine deaminases in the APOBEC3 (A3) family, in particular APOBEC3B; hybridomas that produce such antibodies; and methods of making antibodies that bind to members of the APOBEC3 (A3) family, in particular APOBEC3B.

APOBEC3B is an antiviral enzyme that has been implicated in cancer mutagenesis and is one member of a family of cytidine deaminases in APOBEC3 (A3) family. APOBEC3B is a difficult protein to purify, and this difficulty and its homology to related APOBEC3 family members have previously made the development of antibodies specific for APOBEC3B difficult. The antibodies described herein provide valuable reagents for studying the enzymes of the APOBEC3 (A3) family, in particular APOBEC3B.

This disclosure also describes methods of making antibodies that specifically bind to one or more members of the APOBEC3 (A3) family, in particular APOBEC3B. One embodiment is a method of using epitopes specific to APOBEC3B for the generation of antibodies that specifically bind to APOBEC3B.

This disclosure further describes methods of using antibodies that specifically bind to one or more members of the APOBEC3 (A3) family, in particular APOBEC3B.

Antibodies that bind APOBEC3 proteins

In some embodiments, the antibodies described herein bind members of the APOBEC3 (A3) family, in particular APOBEC3B. In some embodiments, the antibodies bind to primate APOBEC3 (A3) proteins, including, for example, human APOBEC3 (A3) proteins, including, for example, human APOBEC3B (A3B). In one embodiment, an antibody that binds to members of the APOBEC3 (A3) family, in particular APOBEC3B, may have one or more sequences present in the heavy and light chains of the antibodies produced by one or more of the following hybridomas: 5206-235-07, 5210-76-29, 5210-08-15, 5211-110-19, 5211-142-12, 5210-55-19, and 5210-87-13. The amino acid sequences for the light chains of each hybridoma are identified as SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively. The amino acid sequences for the heavy chains of each hybridoma are identified as SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28, respectively.

In some embodiments, the antibody includes one or more Complementarity Determining

Regions (CDRs) present in the heavy and light chains of the antibodies produced by one or more of the following hybridomas: 5206-235-07, 5210-76-29, 5210-08-15, 5211-110-19, 5211-142-12, 5210-55-19, and 5210-87-13 (FIGS. 8B and 9B). The antibody may include CDRs present in the heavy and light chains of the antibodies produced by the same hybridoma and/or different hybridomas.

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5206-235-07 including, for example, the amino acid sequences

QSVYNNND (SEQ ID NO:29) (CDR1), RAS (SEQ ID NO:30) (CDR2), and/or

LGSYDDDVDTCA (SEQ ID NO:31) (CDR3).

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5210-76-29 including, for example, the amino acid sequences

QSLYRNKN (SEQ ID NO:32) (CDR1), YAS (SEQ ID NO:33) (CDR2), and/or

QGEFSCSSADCFA (SEQ ID NO:34) (CDR3).

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5210-08-15 including, for example, the amino acid sequences

QNIYSN (SEQ ID NO:35) (CDR1), GAS (SEQ ID NO:36) (CDR2), and/or QSYVYSSSTADT

(SEQ ID NO:37) (CDR3).

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5211-110-19 including, for example, the amino acid sequences QSVYNNKN (SEQ ID NO:38) (CDR1), GAS (SEQ ID NO:36) (CDR2), and/or

LGEFYCSSIDCLV (SEQ ID NO:39) (CDR3). The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5211-142-12 including, for example, the amino acid sequences HSVYNNNW (SEQ ID NO:40) (CDRl), GAS (SEQ ID NO:36) (CDR2), and/or QGGYSSGDGIA (SEQ ID NO:41) (CDR3).

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5210-55-19 including, for example, the amino acid sequences QSVYKNKN (SEQ ID NO:42) (CDRl), GAS (SEQ ID NO:36) (CDR2), and/or

LGEFSCHSVDCLA (SEQ ID NO:43) (CDR3).

The antibody may include one or more CDRs present in the light chains of the antibodies produced by hybridoma cell line 5210-87-13 including, for example, the amino acid sequences ESVFKKNW (SEQ ID NO:44) (CDRl), GAS (SEQ ID NO:36) (CDR2), and/or AGAFDGNIYP (SEQ ID NO:45) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5206-235-07 including, for example, the amino acid sequences GFDFSS (SEQ ID NO:46) (CDRl), YIDPVFG (SEQ ID NO:47) (CDR2), and/or FCARST (SEQ ID NO:48) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5210-76-29 including, for example, the amino acid sequences GFSFSRG (SEQ ID NO:49) (CDRl), DMNIIAD (SEQ ID NO:50) (CDR2), and/or FCVSGS (SEQ ID NO:51) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5210-08-15 including, for example, the amino acid sequences GFSFSDG (SEQ ID NO:52) (CDRl), CIYDASG (SEQ ID NO:53) (CDR2), and/or FCVKTD (SEQ ID NO:54) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5211-110-19 including, for example, the amino acid sequences GFSLSS (SEQ ID NO:55) (CDRl), FINSDN (SEQ ID NO:56) (CDR2), and/or FCATYR (SEQ ID NO:57) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5211-142-12 including, for example, the amino acid sequences GFSLSS (SEQ ID NO:55) (CDRl), IISSSG (SEQ ID NO:59) (CDR2), and/or FCAREG (SEQ ID NO:60) (CDR3). The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5210-55-19 including, for example, the amino acid sequences GFSISS (SEQ ID NO:61) (CDR1), SISSGG (SEQ ID NO: 62) (CDR2), and/or FCGS (SEQ ID NO:63) (CDR3).

The antibody may include one or more CDRs present in the heavy chains of the antibodies produced by hybridoma cell line 5210-87-13 including, for example, the amino acid sequences GFSLSS (SEQ ID NO: 55) (CDR1), SISSGG (SEQ ID NO: 62) (CDR2), and/or FCGS (SEQ ID NO:63) (CDR3).

In some embodiments, antibody that specifically binds to one family member of the

APOBEC3 family will also specifically bind to other members of the APOBEC3 family, including, for example, APOBEC3A (A3 A); APOBEC3B (A3B); APOBEC3C (A3C); APOBEC3D (A3D) APOBEC3F (A3F); APOBEC3G (A3G); and/or APOBEC3H (A3H) (FIG. 3). For example, antibodies from hybridoma cell line 5210-08-15, hybridoma cell line 5210-76-29, hybridoma cell line 5211-110-19, and hybridoma cell line 5211-142-12 can recognize A3A and A3B; antibodies from hybridoma cell line 5206-235-07 can recognize A3B and A3F; antibodies from hybridoma cell line 5210-55-19, and hybridoma cell line 5210-87-13 can recognize A3 A, A3B, and A3G. (FIG. 3, FIG. 8B, and FIG. 9B)

Methods of making antibodies that bind APOBEC3 proteins

In one or more embodiments, epitopes specific to APOBEC3B may be used to generate antibodies that specifically bind to APOBEC3B. For example,

WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO: 64), representing A3B residues 171-194 and/or CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65), representing A3B residues 354-382, may be used to immunize a mammal to generate antibody-producing cells. The route and schedule of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. The host animal may be, for example, a rabbit, mouse, or any other mammalian subject including human subjects or antibody-producing cells obtained therefrom. In some embodiments, an antigen, an epitope, or a fragment containing the target amino acid sequence may be conjugated to a protein that is immunogenic in the species to be immunized, for example, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, ovalbumin, etc. In addition, those of skill in the art will know of various techniques common in the immunology arts for purification and concentration of polyclonal antibodies, as well as monoclonal antibodies.

The preparation of monoclonal antibodies also is well-known to those skilled in the art. See, e.g., Kohler & Milstein, Nature 1975, 256:495; Coiigan et al., sections 2.5.1-2.6.7; and Harlow et al ., ANTIBODIES: A LABORATORY MANUAL, page 726 (Cold Spring Harbor Pub. 1988). Briefly, monoclonal antibodies can be obtained by injecting an animal including, for example, a mouse or a rabbit, wit a composition including an antigen, verifying the presence of antibody production by analyzing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes wit myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures. Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein A Sepharose, size exclusion chromatography, and ion exchange chromatography.

In some embodiments, antibodies may be produced by host cells and isolated cells. In particular embodiments, the cell is a hybridoma cell. In some additional embodiments, the hybridoma cell line is 5206-235-07, 5210-76-29, 5210-08-15, 5211-110-19, 5211-142-12, 5210-55- 19, and/or 5210-87-13.

In some embodiments, antibodies may also be made by recombinant DNA methods. DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Hybridoma cells or hybridoma cell lines may serve as a source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as, for example, 293F cells, simian COS cells, Chinese hamster ovary (CHO) cells, myeloma cells that do not otherwise produce immunoglobulin protein, etc., to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The

DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of homologous sequences or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.

In some embodiments, an expression vector includes a nucleic acid sequence encoding antibody produced by hybridoma cell line 5206-235-07, hybridoma cell line 5210-76-29, hybridoma cell line 5210-08-15, hybridoma cell line 5211-110-19, hybridoma cell line 5211-142-12, hybridoma cell line 5210-55-19, and/or hybridoma cell line 5210-87-13.

An antibody fragment can be prepared by proteolytic hydrolysis of an intact antibody or by the expression of a nucleic acid encoding the fragment. An antibody fragment can be obtained by pepsin or papain digestion of an intact antibody by conventional methods. For example, an antibody fragment can be produced by enzymatic cleavage of an antibody with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. In some cases, an enzymatic cleavage using pepsin can be used to produce two monovalent Fab' fragments and an Fc fragment directly.

Other methods of cleaving antibodies, such as separation of heavy chains to form

monovalent light heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used to provide fragments that retain some ability to bind (e.g., selectively bind) its epitope.

The antibodies provided herein can be substantially pure. The term "substantially pure" as used herein with reference to an antibody means the antibody is substantially free of other polypeptides, lipids, carbohydrates, and nucleic acids with which it is naturally associated. Thus, a substantially pure antibody is any antibody that is removed from its natural environment and is at least 60 percent pure. A substantially pure antibody can be at least about 65 percent pure, at least about 70 percent pure, at least about 75 percent pure, at least about 80 percent pure, at least about 85 percent pure, at least about 90 percent pure, at least about 95 percent pure, or at least about 99 percent pure.

Methods of using antibodies that bind APOBEC3 (A3) proteins

Antibodies that specifically bind to one or more members of the APOBEC3 (A3) family, in particular APOBEC3B, may be used in a wide variety of applications including, for example, as research reagents for molecular biology, immunology, and/or cancer biology and as clinical reagents for diagnostic and/or prognostic tests for APOBEC3B expression. Antibodies may be used for, for example, enzyme-linked immunosorbent assays (ELISA), immunoblotting (IB), immunoprecipitation (IP), immunohistochemistry (IHC), immunofluorescence (IF), and/or flow cytometry, etc. Assays may be quantitative and/or qualitative, and may detect expression of one or more APOBEC3 (A3) family members in a variety of locations including, for example, in cells, on cell membranes, in tissues, and in bodily fluids. Assays may be used, for example, to determine normal and/or abnormal levels of protein expression.

In some embodiments, a device can include antibody that specifically binds to one or more

APOBEC3 (A3) proteins. In some embodiments, the device includes immobilizing one or more antibodies that specifically bind to one or more APOBEC3 (A3) proteins to a substrate. In some embodiments, the antibody or antibodies may be immobilized on a substrate as part of an antibody microarray, antibody chip, and/or protein chip.

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein. EXAMPLES

Epitope Selection

The full protein sequences of the seven human APOBEC3 (A3) enzymes were obtained from GenBank: APOBEC3A (A3 A) GenBank: AAI26417.1; APOBEC3B (A3B) GenBank:

AAW31743.1; APOBEC3C (A3C) GenBank: AAH11739.1; APOBEC3D (A3D) GenBank:

AIC57731.1; APOBEC3F (A3F) GenBank: AAZ38720.1; APOBEC3G (A3G) GenBank:

AAZ38722.1; APOBEC3H (A3H) GenBank: ACK77774.1.

ClustalW was used to identify regions unique to APOBEC3B (A3B). Two regions were selected for synthesis of peptide immunogens. Peptides were synthesized by Epitomics, Inc.

(Burlingame, CA). Peptide 10, WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO:64), represents A3B residues 171-194. Peptide 12, CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65), represents A3B residues 354-382. Although unique to A3B, extensive homology between family members was unavoidable; peptide 10 shared 20/24 residues with A3F and peptide 12 shared 27/28 residues with A3 A and 25/28 residues with A3G (Table 1). Table 1. Homology of immunization peptides to APOBEC3 proteins

Peptide 10 24 5 24 7 19 20 11 5

Peptide 12 28 27 28 7 7 9 25 6

Immunization and Hybridoma Creation

Two rabbits were immunized with each peptide immunogen (contracted to Epitomics, Inc., Burlingame, CA). The rabbits were given three injections using KLH-conjugated peptide, then two further injections with OVA-conjugated peptide, over the course of 10-12 weeks. Test bleeds from the rabbits were screened for anti-A3B expression by immunoblot (IB) (Towbin et al. Proc. Nat 'l Acad. Sci. USA. 1979; 76(9):4350-4).

Lysates from 293T cells that expressed A3-HA proteins were resolved by SDS-PAGE, transferred to PVDF membrane and immunoblotted with the test bleeds at a dilution of 1/1000 in 50% BLOK (Millipore, Darmstadt, Germany), 0.1% Tween-20 in phosphate buffered saline (PBS).

The bleeds were further screened by immunofluorescence microscopy (IF) of HeLa cells expressing A3B-GFP proteins. Hela cells were fixed in 4% paraformaldehyde (PFA), permeabilized with 0.01% Triton X-100 and then incubated in the rabbit sera (1 :200) in 5% goat serum, 1% BSA, 0.2% Triton X-100 in lx PBS. A3B binding was visualized with anti-rabbit-TRITC (1 :500).

Three anti-A3B positive rabbits (5206, 5210, 5211) were selected for a final immunization boost before the spleens were harvested for B cell isolation and hybridoma production. Hybridoma fusions of 40 ^χ 96-well plates with lymphocytes from the selected rabbits were performed by Epitomics, Inc. (Burlingame, CA). Hybridoma supernatants were screened for reactive anti-A3B antibodies by ELISA screening against recombinant A3Bctd-myc-(HIS)₆ purified protein (Burns et al., 2013, Nature 494(7437):366-370). Representative data are shown in FIG. 1. Candidate hybridomas were expanded.

Hybridoma Screening Immunoblot

Culture media supernatants from ELISA-positive single-clone hybridomas were screened by immunoblot. Lysates from 293T cells that expressed A3-HA proteins (Hultquist et al. J. Virol. 2011; 85, 11220-34) were resolved by SDS-PAGE, transferred to PVDF membrane and

immunoblotted with the hybridoma cell media supernatant (1 :3) in 50% BLOK (Millipore, Darmstadt, Germany), 0.1% Tween 20 in PBS, detected with anti-rabbit IgG IR800CW secondary antibody (LI-COR Biosciences, Lincoln, NE) and imaged by LI-COR imaging (LI-COR Biosciences, Lincoln, NE). Representative data are shown in FIG. 3.

Immunofluorescence

Culture media supernatant from ELISA-positive single-clone hybridomas were screened by immunofluorescence microscopy. HeLa cells expressing fluorescent A3 proteins were fixed in 4% paraformaldehyde, permeabilized with 0.01% Triton X-100 and then incubated in cell media supernatant (1 :5) in 5% goat serum, 1% BSA, 0.2% Triton X-100 in lx PBS. A3B binding was visualized with anti-rabbit-TRITC (1 :500). Representative data are shown in FIG. 4.

Hybridoma expansion

Seven single-clone hybridomas expressing the strongest, most specific anti-A3B sera (5206-235-07, 5210-08-15, 5210-55-19, 5210-76-29, 5210-87-13, 5211-110-19, 5211-142-12) were identified, expanded, and stocks were frozen down.

ELISA

Pure hybridoma clones expressing anti-A3B mAbs were identified by ELISA screening against A3Bctd-myc-(His)₆ purified protein (Burns et al., 2013, Nature 494(7437):366-370).

A3Bctd-myc-(His)6 purified protein (20 ng/well) was immobilized on 96-well ELISA plates through hydrophilic and hydrophobic interactions with the polystyrene plate. Each plate was blocked with 3% BSA, then incubated with undiluted cell media supernatant from the hybridoma clones. Binding was detected with an anti-rabbit HRP secondary antibody (1 :5000), visualized with tetramethylbenzidine (TMB) and quantified by spectroscopy at 450nm. Representative data are shown in FIG. 2.

Monoclonal antibody (mAb) purification

Seven anti-human A3B hybridomas were expanded to 1L, then switched to serum-free media for one week. The media was clarified by centrifugation to remove the cells before it was passed over a Protein A to bind IgG (Boca Scientific Inc., Boca Raton, FL ) (Wilchek et al. Methods Enzymol. 1984; 104:3-55). The monoclonal antibodies were eluted in 0.2 M glycine pH 2.5 and dialyzed into PBS and stored frozen in BSA (0.1 mg/mL) with azide (0.02%). Immunoblots of endogenous A3B in cancer cell lines

Anti-human A3B 5210-87-13 was immunoblotted against various human cancer cell lines that express A3B. Lysates from various cancer cell lines were resolved by SDS-PAGE, transferred to PVDF membrane and immunoblotted with anti-human A3B mAb (5210-87-13) (1 :50) in 5% milk, 0.1% Tween 20 in PBS, detected with anti-rabbit HRP secondary antibody. Expression of A3B was reduced or eliminated when the cells had been treated with A3B shRNA (Burns et al., 2013, Nature 494(7437): 366-370) to knockdown A3B expression, as shown in FIG. 5 A, demonstrating the specificity of this mAb.

Immunofluorescent microscopy of endogenous A3B

Using the anti-human A3B mAb (5210-87-13) endogenous A3B was detected. U20S cells were fixed in 4% paraformaldehyde, permeabilized with 0.01% Triton X-100 and then incubated in anti-human A3B mAb (5210-87-13) in 5% goat serum, 1% BSA, 0.2% Triton X-100 in lx PBS. A3B binding was visualized with anti-rabbit-TRITC (1 :500). Expression of A3B was reduced or eliminated when the cells had been treated with A3B shRNA to knockdown A3B expression as shown in FIG. 5B.

Heavy and Light Chain Sequencing

Rabbit Hybridoma lines derived from the 240E-W fusion partner express variable amounts of an endogenous Ig heavy chain (U.S. Patent No. 7,429,487). This competes with the Ig heavy chain selected from the B lymphocyte for the Ig light chain, resulting in reduced titers and affinity of the desired mAb. To improve the efficacy of these anti-human A3B mAbs Ig heavy and light chain genes were sequenced as follows.

RNA purification

Hybridoma cells (1 x 10⁷ cells) were sheared by centrifugation through RNeasy columns (Qiagen N.V., Hilden, Germany) and RNA was purified using RNeasy columns (Qiagen N. V., Hilden, Germany). cDNA sequencing of the Ig light chain and the constant region of heavy chain genes

RNA purified from the rabbit hybridomas was used as a template for reverse transcription, primed from oligo-dT (3' RACE Adapter GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN (SEQ ID NO: 66)), to synthesize cDNA. The constant region of the rabbit immunoglobulin (Ig) heavy and light chain genes was amplified by polymerase chain reaction (PCR) using 5' primers to the rabbit Ig heavy or light chain gene constant regions (He constant 5' outer primer ATCAGTCTTCCCACTGGCC (SEQ ID NO:67), He constant 5' inner primer GGGACACACCCAGCTCC (SEQ ID NO:68), Ig Lc 5' outer primer CATGAGGGCCCCCACT (SEQ ID NO:69), Ig Lc 5' inner primer

TCCTGCTGCTCTGGCTC (SEQ ID NO: 70)) and a 3' RACE primer (3' RACE outer primer GCGAGCACAGAATTAATACGACT (SEQ ID NO:71), 3' RACE inner primer

CGCGGATCCGAATTAATACGACTCACTATAGG (SEQ ID NO: 72)). The DNA product was ligated into pJETl .2/blunt vector (CloneJET PCR Cloning Kit, Thermo Fisher Scientific, Inc.,

Waltham, MA) and sequenced. The DNA and protein sequences of the light chain genes are shown in FIG. 8A and FIG. 8B. See Table 2 for an aggregate list of primer sequences.

Table 2. Aggregate list of DNA primers. Oligonucleotide primers used in PCR reactions to clone Ig cDNAs from rabbit hybridomas.

cDNA sequencing of the variable region of heavy chain Ig genes

5' RLM-RACE was carried out using the FIRSTCHOICE RLM-RACE Kit (Ambion, Invitrogen Corp., Carlsbad, CA) (Maruyama et al. Gene. 1994; 138(1-2): 171-4). RNA was treated with Calf Intestinal Phosphatase to remove phosphate molecules from degraded mRNA. Next, Tobacco Acid Phosphatase treatment removed the cap from full-length mRNA. Then the 5 'RACE adaptor (RLM-RACE 5' RACE adaptor

GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUGGCUUUGAUGAAA (SEQ ID NO:73)) was ligated onto the mRNA. Reverse transcription was carried out, primed from random hexamers, to synthesized cDNA. The variable region of the rabbit Ig heavy chain genes was amplified by two rounds of PCR, using 5' nested primers to the 5' RACE adaptor (5' RACE outer primer

GCTGATGGCGATGAATGAACACTG (SEQ ID NO:74), 5' RACE inner primer

CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG (SEQ ID NO:75)), and 3' nested primers to rabbit Ig heavy chain constant region (Ig He 5' outer Rev

GGC C AGTGGGA AGAC TGAT (SEQ ID NO:76), Ig He 5' inner Rev

GGAGCTGGGTGTGTCCC (SEQ ID NO: 77), Ig Ch outer (rev) CCGGGAGGTAGCCTTTGACC (SEQ ID NO: 78), Ig Ch inner (rev) GAGGGTGCCCGAGTTCCAG (SEQ ID NO: 79), IgHc 3'- Jh3/5 Rev CRGTGACCAGGGTGCCCTG (SEQ ID NO:80), IgHc 5'-Jh3/5 Rev

CCCCAGRGATCCAACCRRTC (SEQ ID NO:81)). The DNA product was cloned into

pJET1.2/blunt vector (CloneJET PCR Cloning Kit, Thermo Fisher Scientific, Inc., Waltham, MA) and sequenced. The DNA and protein sequences of the heavy chain genes are shown in FIG. 9A and FIG. 9B. See Table 2 for an aggregate list of primer sequences.

Heavy and Light Chain Subcloning

The rabbit hybridoma heavy and light chain Ig genes were amplified by PCR from pJET1.2 using gene-specific primers (Kpn-5' Ig Lc gaggtaccATG GAC ATG AGG GCC CC (SEQ ID NO:82), Xho-3' Ig Lc AGAGCTTCAATAGGGGTGACTGTTAGctcgagacgc (SEQ ID NO:83), 5'- Nhel Ig He CAGgctagcaccATGGAGACTGGGCTGCGC (SEQ ID NO: 84), 3'-Mlul Ig He tagacgcgtTCAtttaCCCGGAGAGCGGGAG (SEQ ID NO: 85)) and sub-cloned into the pcDNA3.1+ eukaryotic expression vector (Life Technologies, Thermo Fisher Scientific, Inc., Waltham, MA). See Table 2 for an aggregate list of primer sequences. Protocols to Express High-Titer Rabbit Anti-Human A3B mAbs

The heavy and light chain Ig genes, for rabbit hybridomas 5210-87-13 and 5211-110-19, were transfected into 293F cells (Life Technologies, Thermo Fisher Scientific, Inc., Waltham, MA) using polyethyleneimine (PEI) at a ratio of 3 : 1, PELDNA, in serum -free Freestyle media (Life Technologies, Thermo Fisher Scientific, Inc., Waltham, MA).

150 mL of culture media was collected, and monoclonal antibodies were purified by Protein A affinity chromatography (Boca Scientific Inc., Boca Raton, FL). The monoclonal antibodies were eluted in 0.2 M glycine pH 2.5 and dialyzed into PBS and stored frozen in BSA (0.1 mg/mL) with azide (0.02%). Monoclonal antibody 5210-87-13 concentration 13 μg /mL, 5211-110-19 36 μg/mL.

The complete disclosure of all patents, patent applications, and publications, and

electronically available material (including, for instance, nucleotide sequence submissions in, e.g., GenBank and RefSeq, and amino acid sequence submissions in, e.g., SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) cited herein are incorporated by reference. In the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements. All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.

Claims

What is claimed is:

1. A monoclonal antibody that specifically binds to one or more APOBEC3 (A3) proteins.

2. The monoclonal antibody of claim 1 wherein the APOBEC3 (A3) protein comprises human APOBEC3B (A3B).

3. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5206-235-07.

4. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5210-76-29.

5. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5210-08-15.

6. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5211-110-19.

7. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5211-142-12.

8. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5210-55-19.

9. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody is produced by hybridoma cell line 5210-87-13.

10. The monoclonal antibody of either of claims 1 or 2 comprising at least one of the amino acid sequences SEQ ID NO : 8, SEQ ID NO : 9, SEQ ID NO : 10, SEQ ID NO : 11 , SEQ ID NO : 12, SEQ ID NO: 13, or SEQ ID NO: 14.

11. The monoclonal antibody of any of claims 1, 2, or 10 comprising at least one of the amino acid sequences SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, or SEQ ID NO:28.

12. The monoclonal antibody of either of claims 1 or 2, wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the light chain comprises three complementarity determining regions (CDRs), and further wherein the first light chain CDR (CDRl) comprises at least one of the amino acid sequences QSVYNN D (SEQ ID NO:29), QSLYR KN (SEQ ID NO:32), QNIYSN (SEQ ID NO:35), QSVYN KN (SEQ ID NO:38), HSVYNNNW (SEQ ID NO:40), QSVYK KN (SEQ ID NO:42), or ESVFKKNW (SEQ ID NO:44).

13. The monoclonal antibody of any of claims 1, 2, or 12, wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the light chain comprises three

complementarity determining regions (CDRs), and further wherein the second light chain CDR (CDR2) comprises at least one of the amino acid sequences RAS (SEQ ID NO:30), YAS (SEQ ID NO:33), or GAS (SEQ ID NO:36).

14. The monoclonal antibody of any of claims 1, 2, 12, or 13 wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the light chain comprises three

complementarity determining regions (CDRs), and further wherein the third light chain CDR (CDR3) comprises at least one of the amino acid sequences LGSYDDDVDTCA (SEQ ID NO:31), QGEFSCSSADCFA (SEQ ID NO:34), QSYVYSSSTADT (SEQ ID NO:37), LGEFYCSSIDCLV (SEQ ID NO:39), QGGYSSGDGIA (SEQ ID NO:41), LGEF SCHS VDCL A (SEQ ID NO:43), or AGAFDGNIYP (SEQ ID NO:45).

15. The monoclonal antibody of any of claims 1, 2, or 12-14, wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises three

complementarity determining regions (CDRs), and further wherein the first heavy chain CDR (CDRl) comprises at least one of the amino acid sequences GFDFSS (SEQ ID NO:46), GFSFSRG (SEQ ID NO:49), GFSFSDG (SEQ ID NO:52), GFSLSS (SEQ ID NO:55), or GFSISS (SEQ ID NO:61).

16. The monoclonal antibody of any of claims 1, 2, or 12-15, wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises three complementarity determining regions (CDRs), and further wherein the second heavy chain CDR (CDR2) comprises at least one of the amino acid sequences YIDPVFG (SEQ ID NO:47),

DMNIIAD (SEQ ID NO:50), CIYDASG (SEQ ID NO:53), FINSDN (SEQ ID NO:56), IISSSG (SEQ ID NO:59), or SISSGG (SEQ ID NO:62).

17. The monoclonal antibody of any of claims 1, 2, or 12-16, wherein the monoclonal antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises three complementarity determining regions (CDRs), and further wherein the third heavy chain CDR (CDR3) comprises at least one of the amino acid sequences FCARST (SEQ ID NO:48), FCVSGS (SEQ ID NO:51), FCVKTD (SEQ ID NO:54), FCATYR (SEQ ID NO:57), FCAREG (SEQ ID NO:60), or FCGS (SEQ ID NO:63).

18. A method of using any of the antibodies of claims 1-17.

19. The method of claim 18 further comprising using the antibody as research reagent.

20. The method of claim 18 further comprising using the antibody for at least one of a diagnostic test and a prognostic test.

21. The method of any of claims 18-20, further comprising detecting the expression of one or more APOBEC3 (A3) proteins.

22. The method of any of claims 18-21, further comprising detecting the expression of APOBEC3B (A3B).

23. The method of any of claims 18-21, further comprising performing at least one of enzyme- linked immunosorbent assays (ELISA), immunoblotting (IB), immunoprecipitation (IP), immunohistochemistry (IHC), immunofluorescent microscopy (IF), and flow cytometry (FLOW).

24. A method of producing an antibody comprising the steps of: immunizing a host animal with at least one of WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO:64) and CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65); and

harvesting a cell that produces antibodies to one or more members of the APOBEC3 (A3) family.

25. The method of claim 24 comprising immunizing the host animal with both

WYKFDENYAFLHRTLKEILRYLMD (SEQ ID NO: 64) and

CPFQPWDGLEEHSQALSGRLRAILQNQGN (SEQ ID NO:65).

26. A device comprising the monoclonal antibody of any of claims 1-17 immobilized to a substrate.

27. A hybridoma cell line 5206-235-07.

28. A hybridoma cell line 5210-76-29.

29. A hybridoma cell line 5210-08-15.

30. A hybridoma cell line 5211-110-19.

31. A hybridoma cell line 5211 - 142- 12.

32. A hybridoma cell line 5210-55-19.

33. A hybridoma cell line 5210-87-13.

34. A vector expressing a nucleic acid sequence encoding antibody produced by at least one of hybridoma cell line 5206-235-07, hybridoma cell line 5210-76-29, hybridoma cell line 5210-08-15, hybridoma cell line 5211-110-19, hybridoma cell line 5211-142-12, hybridoma cell line 5210-55- 19, and hybridoma cell line 5210-87-13.